KR20250011136A - 암의 치료를 위한 smarca4 단백질 분해제로서의 6,6a,7,8,9,10-헥사하이드로-5h-피라지노[1',2':4,5]피라지노[2,3-c]피리다진 유도체 - Google Patents

암의 치료를 위한 smarca4 단백질 분해제로서의 6,6a,7,8,9,10-헥사하이드로-5h-피라지노[1',2':4,5]피라지노[2,3-c]피리다진 유도체 Download PDF

Info

Publication number
KR20250011136A
KR20250011136A KR1020247040958A KR20247040958A KR20250011136A KR 20250011136 A KR20250011136 A KR 20250011136A KR 1020247040958 A KR1020247040958 A KR 1020247040958A KR 20247040958 A KR20247040958 A KR 20247040958A KR 20250011136 A KR20250011136 A KR 20250011136A
Authority
KR
South Korea
Prior art keywords
pyrazino
methyl
hexahydro
hydroxyphenyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247040958A
Other languages
English (en)
Korean (ko)
Inventor
존 에이. 로즈
코리 하워드 바슈
송 메이
클레 라조르 버시
다니엘 줄리 빔 로스
카타리나 롤핑
샤오웨이 우
아르템 슈바르츠바르트
앤드류 폴 콤브스
리앙 루
Original Assignee
프렐루드 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프렐루드 테라퓨틱스 인코포레이티드 filed Critical 프렐루드 테라퓨틱스 인코포레이티드
Publication of KR20250011136A publication Critical patent/KR20250011136A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020247040958A 2022-05-10 2023-05-09 암의 치료를 위한 smarca4 단백질 분해제로서의 6,6a,7,8,9,10-헥사하이드로-5h-피라지노[1',2':4,5]피라지노[2,3-c]피리다진 유도체 Pending KR20250011136A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340185P 2022-05-10 2022-05-10
US63/340,185 2022-05-10
PCT/US2023/066755 WO2023220577A1 (en) 2022-05-10 2023-05-09 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20250011136A true KR20250011136A (ko) 2025-01-21

Family

ID=86771366

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040958A Pending KR20250011136A (ko) 2022-05-10 2023-05-09 암의 치료를 위한 smarca4 단백질 분해제로서의 6,6a,7,8,9,10-헥사하이드로-5h-피라지노[1',2':4,5]피라지노[2,3-c]피리다진 유도체

Country Status (10)

Country Link
US (1) US20230365576A1 (enExample)
EP (1) EP4522621A1 (enExample)
JP (1) JP2025521091A (enExample)
KR (1) KR20250011136A (enExample)
CN (1) CN119487036A (enExample)
AU (1) AU2023269778A1 (enExample)
CA (1) CA3252552A1 (enExample)
IL (1) IL316891A (enExample)
MX (1) MX2024013843A (enExample)
WO (1) WO2023220577A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2026090411A1 (en) 2024-10-23 2026-04-30 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
CN119504710B (zh) * 2024-11-18 2025-10-17 昆明医科大学 靶向降解PRMT5的PROTACs化合物及其应用
CN121873038A (zh) * 2026-03-16 2026-04-17 南开大学 针对结直肠癌的靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2023529908A (ja) * 2020-06-09 2023-07-12 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法

Also Published As

Publication number Publication date
JP2025521091A (ja) 2025-07-08
WO2023220577A1 (en) 2023-11-16
MX2024013843A (es) 2025-02-10
IL316891A (en) 2025-01-01
CA3252552A1 (en) 2023-11-16
CN119487036A (zh) 2025-02-18
AU2023269778A1 (en) 2024-12-12
US20230365576A1 (en) 2023-11-16
EP4522621A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
ES3034380T3 (en) Brm targeting compounds and associated methods of use
US12448389B2 (en) BRM targeting compounds and associated methods of use
EP4522621A1 (en) 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
KR20250065894A (ko) Brm 표적화 화합물 및 연관된 사용 방법
KR20250107915A (ko) Brm 표적화 화합물 및 연관된 사용 방법
CA3205652A1 (en) Cdk inhibitors and their use as pharmaceuticals
KR20250036135A (ko) 유비퀴틴 리가제 결합 모이어티를 갖는 kat6 표적화 화합물
WO2025101738A1 (en) Brm targeting compounds and associated methods of use
US20250161289A1 (en) KAT6 Targeting Compounds
WO2025184459A1 (en) Brm and brg1 targeting compounds and associated methods of use
HK40128204A (en) Brm targeting compounds and associated methods of use
EA050840B1 (ru) Brm направленные соединения и связанные способы применения
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
EA052189B1 (ru) Соединения, нацеленные на brm, и связанные с ними способы использования

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000